Black Diamond Therapeutics, Inc. (BDTX) Dividend History

Company News

• Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology Therapy

  Servier and Black Diamond Therapeutics have announced a global licensing agreement for BDTX-4933, a targeted oncology therapy in Phase 1 development. Servier will lead the development and commercialization of the therapy, with Black Diamond receiving an upfront payment and potential milestone and royalty payments.

  GlobeNewswire Inc.
• BRAF Inhibitors Market to Register Incremental Growth During the Study Period (2020–2034) | DelveInsight

  The BRAF inhibitor market is expected to grow significantly due to the increasing number of cancer patients, rise in biomarker testing, and ongoing research and development of next-generation BRAF-targeting therapies.

  GlobeNewswire Inc.

  Featured Companies: CCCC PFE
• Black Diamond Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

  Black Diamond Therapeutics reported encouraging initial Phase 2 data for BDTX-1535 in patients with recurrent EGFR-mutant NSCLC. The company also presented real-world data on treatment practices and outcomes for newly diagnosed NSCLC patients with non-classical EGFR mutations. Black Diamond expects to provide clinical updates and regulatory feedback on BDTX-1535 in Q1 2025.

  GlobeNewswire Inc.
• Black Diamond Therapeutics Announces Restructuring Plan to Focus Resources on BDTX-1535 and Extend Cash Runway

  Black Diamond Therapeutics is focusing its resources on advancing its lead program BDTX-1535 for EGFR-mutant non-small cell lung cancer, while deprioritizing its BDTX-4933 program. The company is implementing a restructuring plan to extend its cash runway into Q2 2026.

  GlobeNewswire Inc.
• Black Diamond Therapeutics to Host Webcast Presentation of Initial Phase 2 BDTX-1535 Data in Patients With Recurrent EGFRm NSCLC

  Black Diamond Therapeutics will host a webcast to disclose initial phase 2 clinical trial results for BDTX-1535 in patients with recurrent EGFRm NSCLC on September 23, 2024.

  GlobeNewswire Inc.